DEC1

Official Full Name

deleted in esophageal cancer 1

Synonyms

CTS9

Cat.No.	Product Name	Price
CSC-DC004174	Panoply™ Human DEC1 Knockdown Stable Cell Line	Inquiry
CSC-SC004174	Panoply™ Human DEC1 Over-expressing Stable Cell Line	Inquiry

Cat.No.	Product Name	Price
LV10523L	human DEC1 (NM_017418) lentivirus particles	Inquiry

Cat.No.	Product Name	Price
SHH276257	shRNA set against Human DEC1 (NM_017418.2)	Inquiry

Cat.No.	Product Name	Price
MiUTR4H-TG02651	DEC1 miRNA 3'UTR clone	Inquiry

Detailed Information

Esophageal cancer, a severe malignancy with a high mortality rate, has been a topic of extensive research in recent years. One of the key genes that have been identified in the development of this disease is DEC1 (Deleted in Esophageal Cancer 1). DEC1, deleted in esophageal cancer 1, is a candidate TSG characterized by a high LOH frequency and reduced expression in tumors and the ability to suppress cancer cell growth in vitro. There is some controversy with respect to the chromosomal location of DEC1: the gene maps to 9q33.1, according to the Ensembl and UCSC databases, and 9q32, according to the NCBI database.

Role of DEC1 in Esophageal Cancer

DEC1 is located in a candidate region for inhibition of esophageal cancer, 9q32. DEC1 expression is reduced or absent in 62% of esophageal cancer cell lines and 53% of primary esophageal cancer cells. Although we did not find mutations in this gene in tumors, the reduced expression of DEC1 in esophageal cancer, the high frequency of 9q32 LOH in esophageal cancer, and the fact that the DEC1 cDNA has growth-inhibitory activity in vitro suggest that additional studies of the DEC1 gene and its products in relation to carcinogenesis may be warranted.

The key genes implicated in the development of esophageal squamous cell carcinoma (ESCC) remain to be elucidated. Previous studies have shown extensive genomic alterations on chromosome 9 in ESCC. One study utilized a single chromatin transfer approach to provide functional evidence and narrowed down the critical region (CR) leading to tumor-suppressive activity on chromosome 9 to a 2.4 Mb region between markers D9S1798 and D9S61, which maps to 9q33-q34. Interestingly, a high prevalence of allelic deletions in this CR was also observed in primary ESCC tumors by microsatellite typing. Allelic deletions were found in 30/34 (88%) tumors, with heterozygous deletion (LOH) frequencies ranging from 67% to 86%. No or low expression of the 9q32 tumor suppressor gene (TSG) candidate DEC1 (deleted gene 1 in esophageal cancer) was detected in four Asian ESCC cell lines. Transfectants stably expressing DEC1 provided functional evidence of tumor growth inhibition in nude mice and reduced expression of DEC1 in tumor isolates generated after prolonged selection in vivo. In primary ESCC tumors, the LOH of the DEC1 region was as high as 74%. DEC1 is a candidate TSG that may be involved in the progression of ESCC.

Clinical association of DEC1 in lymph node metastatic oesophageal SCC, early onset oesophageal SCC and familial oesophageal SCC development. Subcellular localization of DEC1 and its expression in oesophageal SCC tissues provide important insight for further deciphering the molecular mechanism of DEC1 in oesophageal SCC development.

References:

Kunimoto Y, Nakano S, Kataoka H, Shimada Y, Oshimura M, Kitano H. Deleted in Esophageal Cancer 1(DEC1) is down-regulated and contributes to migration in head and neck squamous cell carcinoma cell lines. ORL J Otorhinolaryngol Relat Spec. 2011;73(1):17-23. doi:10.1159/000320997
Nishiwaki T, Daigo Y, Kawasoe T, Nakamura Y. Isolation and mutational analysis of a novel human cDNA, DEC1 (deleted in esophageal cancer 1), derived from the tumor suppressor locus in 9q32. Genes Chromosomes Cancer. 2000;27(2):169-176.

Quick Inquiry

DEC1

You might be looking for:

Detailed Information